Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to calicheamicin, that is rapidly internalized after binding to CD33. This is followed by intracellular release of calicheamicin, which induces double-stranded DNA breaks, cell cycle arrest, and apoptosis. So GO is a more selective agent for acute myeloid leukemia (AML), because the CD33 antigen is expressed on AML, while it is not expressed on normal hematopoietic stem cells and nonhematopoietic tissues. However, some studies indicated that this agent showed resistance to refractory AML cells via various mechanisms, and that there were no potent effects. In this study, we report a 76-year-old female with recurrent AML who responded to single therapy with GO, achieving complete remission for more than 1 year after the start of administration, although additional remission induction was impossible. The response to GO can be stratified with reference to the response to conventional chemotherapy.
[Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Publishing Authors By Initials
[Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Journal Published:
PUBLICATION TYPE: Journal Article
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
VOLUME: 34
Page Numbers: 1881-3
Journal Abbreviation: Gan To Kagaku Ryoho
ISSN: 0385-0684
DAY: 21
MONTH: Nov
YEAR: 2007
[Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Information
Number of References:
LANGUAGE: jpn
NlmUniqueID: 7810034
[Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient] Information
Substance Name:
Registry Number:
Grant and Affiliation Information for [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient]
AFFILIATION: Dept. of Hematology, Aomori Prefectural Central Hospital.
Country: Japan
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Gan To Kagaku Ryoho
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient Related Publications